1. Umehara H, Okazaki K, Kawa S, Takahashi H, Goto H, Matsui S, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol. 2021;31:529–33.
2. Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732–8.
3. 厚⽣労働省難治性疾患克服研究事業. IgG4 関連疾患包括診断基準2011. ⽇内会誌. 2012;101:795〜804.
4. Tanaka A, Moriyama M, Nakashima H, Miyake K, Hayashida JN, Maehara T, et al. Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease. Arthritis Rheum.2012;64:254–63.
5. Masaki Y, Dong L, Kurose N, Kitagawa K, Morikawa Y, Yamamoto M, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis. 2009;68:1310–5.
6. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: An odd antibody. Clin Exp Allergy. 2009;39:469–77.
7. Stone JH, Zen Y, Deshpande V. IgG4-Related Disease. N Engl J Med. 2012;366:539–51.
8. Satoguina JS, Weyand E, Larbi J, Hoerauf A. T Regulatory-1 Cells Induce IgG4 Production by B Cells: Role of IL-10. J Immunol. 2005;174:4718–26.
9. Tsuboi H, Iizuka M, Takahashi H, Asashima H, Hirota T, Kondo Y, et al. Pathogenesis of IgG4-related disease-Molecular biological approaches. Clin Rheumatol Relat Res. 2017;29:128–39.
10. Shiokawa M, Kodama Y, Kuriyama K, Yoshimura K, Tomono T, Morita T, et al. Pathogenicity of IgG in patients with IgG4-related disease. Gut. 2016;65:1322–32.
11. Maehara T, Mattoo H, Ohta M, Mahajan VS, Moriyama M, Yamauchi M, et al. Lesional CD4+IFN-γ+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis. Ann Rheum Dis. 2017;76:377–85.
12. Akiyama M, Yasuoka H, Yamaoka K, Suzuki K, Kaneko Y, Kondo H, et al. Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4- related disease. Arthritis Res Ther. 2016;18:1–14.
13. Wallace ZS, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015;74:190– 5.
14. Yamamoto M, Takahashi H, Shinomura Y. Mechanisms and assessment of IgG4-related disease: Lessons for the rheumatologist. Nat Rev Rheumatol. 2014;10:148–59.
15. Tsuboi H, Nakai Y, Iizuka M, Asashima H, Hagiya C, Tsuzuki S, et al. DNA microarray analysis of labial salivary glands in IgG4-related disease: Comparison with Sjögren’s syndrome. Arthritis Rheumatol. 2014;66:2892– 9.
16. Furukawa S, Moriyama M, Tanaka A, Maehara T, Tsuboi H, Iizuka M, et al. Preferential M2 macrophages contribute to fibrosis in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz’s disease. Clin Immunol. 2015;156:9–18.
17. Akiyama M, Yasuoka H, Yoshimoto K, Takeuchi T. CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4- related disease. Ann Rheum Dis. 2018;77:1386–7.
18. Tsuboi H, Iizuka-Koga M, Asashima H, Takahashi H, Kudo H, Ono Y, et al. Upregulation and pathogenic roles of CCL18-CCR8 axis in IgG4-related disease. Mod Rheumatol. 2020;30:729–37.
19. Aguado E, Richelme S, Nuñez-Cruz S, Miazek A, Mura AM, Richelme M, et al. Induction of T helper type 2 immunity by a point mutation in the LAT adaptor. Science (80- ). 2002;296:2036–40.
20. Yamada K, Zuka M, Ito K, Mizuguchi K, Kakuchi Y, Onoe T, et al. LatY136F knock-in mouse model for human IgG4-related disease. PLoS One. 2018;13:1–14.
21. Cui Y, Masaki K, Zhang X, Yamasaki R, Fujii T, Ogata H, et al. A novel model for treatment of hypertrophic pachymeningitis. Ann Clin Transl Neurol. 2019;6:431–44.
22. Qu WM, Miyazaki T, Terada M, Okada K, Mori S, Kanno H, et al. A novel autoimmune pancreatitis model in MRL mice treated with polyinosinic:polycytidylic acid. Clin Exp Immunol. 2002;129:27–34.
23. Ishiguro N, Moriyama M, Furusho K, Furukawa S, Shibata T, Murakami Y, et al. Activated M2 Macrophages Contribute to the Pathogenesis of IgG4-Related Disease via Toll-like Receptor 7/Interleukin-33 Signaling. Arthritis Rheumatol. 2020;72:166–78.
24. Panina-Bordignon P, Papi A, Mariani M, Di Lucia P, Casoni G, Bellettato C, et al. The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Invest. 2001;107:1357–64.
25. Islam SA, Ling MF, Leung J, Shreffler WG, Luster AD. Identification of human CCR8 as a CCL18 receptor. J Exp Med. 2013;210:1889–98.
26. Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjögren’s syndrome in labial salivary gland biopsies. Oral Surgery, Oral Med Oral Pathol. 1974;37:217–29.
27. Asano K, Takahashi N, Ushiki M, Monya M, Aihara F, Kuboki E, et al. Intestinal CD169 + macrophages initiate mucosal inflammation by secreting CCL8 that recruits inflammatory monocytes. Nat Commun. Nature Publishing Group; 2015;6:1–14.
28. Islam SA, Chang DS, Colvin RA, Byrne MH, McCully ML, Moser B, et al. Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+TH2 cells. Nat Immunol. 2011;12:167–77.
29. Barsheshet Y, Wildbaum G, Levy E, Vitenshtein A, Akinseye C, Griggs J, et al. CCR8+FOXp3+ Treg cells as master drivers of immune regulation. Proc Natl Acad Sci U S A. 2017;114:6086–91.
30. Spinetti G. The chemokine receptor CCR8 mediates rescue from dexamethasone-induced apoptosis via an ERK-dependent pathway. J Leukoc Biol. 2003;73:201–7.
31. Segar, R., Krebs EG. The MAPK signaling cascade. FASEB J. 1995;9:726–35.
32. Ihn H, Tamaki K. Oncostatin M Stimulates the Growth of Dermal Fibroblasts Via a Mitogen-Activated Protein Kinase-Dependent Pathway. J Immunol. 2000;165:2149–55.
33. Atamas SP, Luzina IG, Choi J, Tsymbalyuk N, Carbonetti NH, Singh IS, et al. Pulmonary and Activation-Regulated Chemokine Stimulates Collagen Production in Lung Fibroblasts. Am J Respir Cell Mol Biol. 2003;29:743–9.
34. Masuoka M, Shiraishi H, Ohta S. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest. 2012;122:2590–600.
35. Jinnin M, Ihn H, Yamane K, Tamaki K. Interleukin-13 stimulates the transcription of the human α2(I) collagen gene in human dermal fibroblasts. J Biol Chem. 2004;279:41783–91.
36. Mattoo H, Mahajan VS, Maehara T, Deshpande V. Clonal expansion of CD4+cytotoxic T lymphocytes in patients with IgG 4 -related disease. J Allergy Clin Immunol. 2016;138:825–38.
37. Salomon I, Netzer N, Wildbaum G, Schif-Zuck S, Maor G, Karin N. Targeting the Function of IFN-γ-Inducible Protein 10 Suppresses Ongoing Adjuvant Arthritis. J Immunol. 2002;169:2685–93.
38. Wildbaum G, Netzer N, Karin N. Plasmid DNA Encoding IFN-γ-Inducible Protein 10 Redirects Antigen-Specific T Cell Polarization and Suppresses Experimental Autoimmune Encephalomyelitis. J Immunol. 2002;168:5885–92.
39. Zohar Y, Wildbaum G, Novak R, Salzman AL, Thelen M, Alon R, et al. CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J Clin Invest. 2017;127:3913.
40. Meiron M, Zohar Y, Anunu R, Wildbaum G, Karin N. CXCL12 (SDF-1α) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells. J Exp Med. 2008;205:2643– 55.